Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoling Luo

Showing results (161-170 of 166) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 166 results.
Cancers|July 13, 2024
Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in NeuroblastomaStacey Stauffer, Jacob S Roth, Edjay R Hernandez, et al.
Science Translational Medicine|July 6, 2018
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcomaMarielle E Yohe, Berkley E Gryder, Jack F Shern, et al.
Gastroenterology|February 16, 2020
Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in MiceDan Li, Nan Li, Yi-Fan Zhang, et al.
Molecular Cancer Therapeutics|November 7, 2020
Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and NeuroblastomaJoshua T Kowalczyk, Xiaolin Wan, Edjay R Hernandez, et al.
Cancer Cell|December 24, 2013
Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinomaJin Hou, Ye Zhou, Yuanyuan Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma ModelsKatie E Hebron, Xiaolin Wan, Jacob S Roth, et al.
Pageof 17

Showing results (161-170 of 166) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 166 results.
Cancers|July 13, 2024
Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in NeuroblastomaStacey Stauffer, Jacob S Roth, Edjay R Hernandez, et al.
Science Translational Medicine|July 6, 2018
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcomaMarielle E Yohe, Berkley E Gryder, Jack F Shern, et al.
Gastroenterology|February 16, 2020
Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in MiceDan Li, Nan Li, Yi-Fan Zhang, et al.
Molecular Cancer Therapeutics|November 7, 2020
Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and NeuroblastomaJoshua T Kowalczyk, Xiaolin Wan, Edjay R Hernandez, et al.
Cancer Cell|December 24, 2013
Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinomaJin Hou, Ye Zhou, Yuanyuan Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2022
The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma ModelsKatie E Hebron, Xiaolin Wan, Jacob S Roth, et al.
Pageof 17